Effects of hypolipemic drugs on the osteoprotegerin – sRANKL system in patients with coronary artery disease

• References

• 1 Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet 2001; 358: 257-259.
• 2 McFarlane SI, Muniyappa R, Shin JJ. et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?. Endocrine 2004; 23: 1-10.
• 3 Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-553.
• 4 Price PA, June HH, Buckley JR. et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616.
• 5 Jono S, Ikari Y, Shioi A. et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194.
• 6 Vik A, Brodin E, Borvik T. et al. Serum osteoprotegerin in young survivors of myocardial infarction. Thromb Haemost 2006; 95: 881-885.
• 7 Edwards CJ, Spector TD. Statins as modulators of bone formation. Arthritis Res 2002; 04: 151-153.
• 8 Viereck V, Grundker C, Blaschke S. et al. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 2005; 96: 1244-1253.
• 9 Undas A, Celinska-Lowenhoff M, Domagala TB. et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005; 94: 193-199.
• 10 Ziolkowska M, Kurowska M, Radzikowska A. et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002; 46: 1744-1753.
• 11 Kaji H, Kanatani M, Sugimoto T. et al. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 2005; 37: 589-592.
• 12 Meier CR, Schlienger RG, Kraenzlin ME. et al. H. HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc 2000; 283: 3205-3210.
• 13 Kiechl S, Schett G, Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.